Day 2 :
Lodz University of Technology, Poland
Time : 09:30 - 10:00
Jacek Ulanski is an Professor at Lodz University of Technology in Lodz, Poland since 1994; Full Professor since 2001; since 1999, he is the Head of Department of Molecular Physics. His research work lies in physical properties of polymers, molecular crystals, composites and nanocomposites, hydrogels, molecular relaxations, phase transitions, intermolecular interactions, transport of energy and charges. Developing of new materials and new processing techniques (like reticulate doping or zone-casting) for organic opto-electronic devices; construction and characterisation of OFETs, OLEDs, photovoltaics, photodiodes. He is a Supervisor of 21 PhD thesis, author and co-author of over 230 papers and monographs, many patents and over 100 lectures at international conferences.
Printed organic electronics is an emerging technology which attracts a lot of interest due to very broad range of possible applications. However in spite of very intensive reasearch carried out since several years in academic and industrial laboratories, there are still many unsolved problems hindering implementation of this new technology. Concerning printed organic light emitting diodes (OLEDs) among different obstacles two have fundamental meaning – low efficiency and poor solution processability. In this work we will present how one increase efficiency of electroluminescence by emplying triplet excited states using as the emitters new iridium complexes, and how one improve processability of the emissive layers by means of host-guest approach with ambipolar polymer as the host matrix.
Sechenov University, Russia
Keynote: Personalized and precision medicine as a unique healthcare model to secure the national and international biosafety
Time : 10:00 - 10:30
Sergey Suchkov was born in the City of Astrakhan, Russia. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, maintained his PhD at the I.M. Sechenov Moscow Medical Academy and Inst of Med Enzymology. In 2001, and then his Doctor Degree at the Nat Inst of Immunology in Russia. From 1989 through 1995, was being a Head of the Lab of Clin Immunology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004 - a Chair of the Dept for Clin Immunology, Moscow Clin Research Institute (MONIKI). In 1993-1996, was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.
A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). To achieve the implementation of PM concept, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of biopredictors of hidden abnormalities long before the disease clinically manifests itself. Each decision-maker values the impact of their decision to use PPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost effective use of health care resources. A lack of medical guidelines has been identified by the majority of responders as the predominant barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of PPM!
Implementation of PPM requires a lot before the current model “physician-patient” could be gradually displaced by a new model “medical advisor-healthy person-at-risk”. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM to elicit the content of the new branch.
Suntec Medical, USA
Keynote: A breakthrough in enhancing the therapeutic index of immunotherapy and target therapy for cancer
Time : 10:30 - 11:00
Pauline Y Lau has been working in medical industry for over 35 years with experiences in both pharmaceutical and in-vitro medical device (IVD). Her accomplishment is well recognized by the international societies in the last 20 years. Suntec Medical Inc., USA (pharmaceutical company) under her leadership has successfully registered pharmaceutical products globally. Currently, the company is developing a portfolio of cancer therapies including immuno-oncology and targeted therapies utilizing its proprietary MNC technology platform. She is global Expert and accomplished Researcher in Precision Medicine. She was an Executive Director in Integrated Medicine at Roche Pharmaceuticals.
Statement of the Problem: A common issue for anti-cancer drugs are the strong toxicity and low efficacy of most therapies. This is especially an issue to many immunotherapies such as IL12. This is caused by not enough drugs enter tumor tissues to have satisfactory efficacy, and left majority of the drugs enter normal tissues to cause high toxicities to the normal tissues. Target drug delivery technologies such as liposomes are effective in improving the therapeutic index (efficacy/toxicity) of small molecular chemotherapies. But, no effective technology has been demonstrated to effectively enhancing the therapeutic index of protein drugs including monoclonal antibody targeted therapies.
Breakthrough in Cancer Treatment: A new nanotechnology, MNC technology, has been dramatically improved the therapeutic index of all classes of anti-cancer drugs. Successful applications are demonstrated by Trastuzumab (monoclonal antibody), Interferon alpha (immunotherapy) and Sunitinib (chemotherapy).
Principle of technology: MNC technology is a micelle nanocomplex that can reversably bind to drugs, target deliver majority of the drug to the tumor site plus effectively slow release of the drug from circulation to tumor to enhance the full usage of the drug and reduce toxicity.